MKI67 and breast carcinoma: Similarly, in a 2008 meta-analysis by Stuart-Harris et al. [50], forty-three studies including 15,790 patients with breast cancer and Ki-67 data were evaluated based on Ki-67 cutoff points ranging from 0% to 28.6%.